Perrot A, et al. - Researchers intended to define a cytogenetic risk classification in order to adapt multiple myeloma (MM) treatment to risk, as the current definition of high-risk profile is restrictive and oversimplified. For this purpose, they used a cohort of newly diagnosed patients with MM and simultaneously assessed the prognostic influence of del(17p); t(4;14); del(1p32); 1q21 gain; and trisomies 3, 5, and 21. They derived data from 635 patients enrolled in four trials implemented by the Intergroupe Francophone du Myélome. Clinically relevant six cytogenetic aberrations were identified, and for all patients, a prognostic index (PI) was calculated that was based on the parameter estimates of the multivariable Cox model. According to the findings, improved classification of newly diagnosed patients with MM in the high-risk group was obtained with the cytogenetic PI vs current classifications.